{"id":692871,"date":"2022-10-06T08:32:36","date_gmt":"2022-10-06T12:32:36","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/cabaletta-bio-to-present-at-the-29th-annual-congress-of-the-european-society-of-gene-cell-therapy\/"},"modified":"2022-10-06T08:32:36","modified_gmt":"2022-10-06T12:32:36","slug":"cabaletta-bio-to-present-at-the-29th-annual-congress-of-the-european-society-of-gene-cell-therapy","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/cabaletta-bio-to-present-at-the-29th-annual-congress-of-the-european-society-of-gene-cell-therapy\/","title":{"rendered":"Cabaletta Bio to Present at the 29th Annual Congress of the European Society of Gene &amp; Cell Therapy"},"content":{"rendered":"<div class=\"mw_release\">\n<p>PHILADELPHIA, Oct.  06, 2022  (GLOBE NEWSWIRE) &#8212; Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of targeted cell therapies for patients with autoimmune diseases, today announced that it will present clinical and translational data from the DesCAARTes\u2122 trial of DSG3-CAART in adults with mucosal-dominant pemphigus vulgaris (mPV) in a poster presentation at the upcoming 29th Annual Congress of the European Society of Gene &amp; Cell Therapy (ESGCT), which is being held at the Edinburgh International Conference Centre in Edinburgh, Scotland from October 11-14, 2022.<\/p>\n<p>Details of the poster presentation are as follows:<\/p>\n<p>\n        <strong>Title:<\/strong> Characterization of DSG3-CAART cells prior to &amp; following adoptive transfer in mucosal Pemphigus Vulgaris<br \/><strong>Poster ID Number:<\/strong> P370<br \/><strong>Session Title: <\/strong>Poster session II <br \/><strong>Date and Time:<\/strong> Thursday, October 13, 2022, 5:30 p.m. \u2013 7:15 p.m. BST<br \/><strong>Presenter: <\/strong>Samik Basu, M.D., Chief Scientific Officer at Cabaletta Bio<\/p>\n<p>Additional information, including the ESGCT abstract as submitted, will be made available to registrants on the first day of the Congress, can be found on the ESGCT website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=CYE1MKItUSGbs_ty0TH5sFrFovqKendtHwE4pQpVvJAnLZqA33X_j9tZffj5AHlgoGgwm0Q3orrid5tVQPGJOfYBBSqwSfC9H1sOxwxlUzg=\" rel=\"nofollow noopener\" target=\"_blank\"><u>www.esgctcongress.com<\/u><\/a>. Presentation materials will be made available under the Posters &amp; Publications section of the Company\u2019s website shortly after the event.<\/p>\n<p>\n        <strong>About CAAR T Cell Therapy<\/strong><br \/>\n        <br \/>Chimeric AutoAntibody Receptor (CAAR) T cells are designed to selectively bind and eliminate only disease-causing B cells, while sparing the normal B cells that are essential for human health. CAAR T cells are based on the chimeric antigen receptor (CAR) T cell technology. While CAR T cells typically contain a CD 19-targeting molecule, CAAR T cells express an autoantibody-targeted antigen on their surface. The co-stimulatory domain and the signaling domain of both a CAR T cell and a CAAR T cell carry out the same activation and cytotoxic functions. Thus, Cabaletta\u2019s CAARs are designed to direct the patient\u2019s T cells to kill only the pathogenic cells that express disease-causing autoantibodies on their surface, potentially leading to complete and durable remission of disease while sparing all other B cell populations that provide beneficial immunity from infection.<\/p>\n<p>\n        <strong>About Cabaletta Bio<\/strong><br \/>\n        <br \/>Cabaletta Bio (Nasdaq: CABA) is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies that have the potential to provide a deep and durable, perhaps curative, treatment for patients with autoimmune diseases. The CABA\u2122 platform, in combination with Cabaletta Bio\u2019s proprietary technology, has advanced a growing pipeline that currently includes potential treatments for patients with mucosal pemphigus vulgaris, MuSK-associated myasthenia gravis, PLA2R-associated membranous nephropathy, mucocutaneous pemphigus vulgaris and hemophilia A with FVIII alloantibodies. Cabaletta Bio\u2019s headquarters are located in Philadelphia, PA. For more information, visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=L9ARUZnee4lwuSuoi3yhHbqnxJEu2l_TbpoEJ_p7SN7qT_tCoXEfGjV5o51R_h5omTIoJg65ogf6dIJp0I4G5Yav4CSmDqqXoD6HsaDuKUs=\" rel=\"nofollow noopener\" target=\"_blank\"><u>www.cabalettabio.com<\/u><\/a> and follow us on LinkedIn.<\/p>\n<p>\n        <strong>Contacts:<\/strong><br \/>\n        <br \/>Anup Marda<br \/>Chief Financial Officer<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=NYdVYFKj87RJNBjCRAaxKgREiD-dD-4_FPx1DYklXqB1XoQtELI_-kMAHDbkIl7qS-PJFsUL1_x4hBeTBzJdhRxt4pEHm-bhRIjXffa62fEgWZS30qS9gTqS2Q0T7CK_\" rel=\"nofollow noopener\" target=\"_blank\"><u>investors@cabalettabio.com<\/u><\/a><\/p>\n<p>Sarah McCabe<br \/>Stern Investor Relations, Inc.<br \/>212-362-1200<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=hk7bqevgegEj4Z17sLOrhpdXpf2uQAEy1wl5CO6wMfrQhkK1-i2X57alIfWSY0-KZtKTqEnUzt0I4baKXeCcexTCAA9UY4w_sPrmW-6Xp-U=\" rel=\"nofollow noopener\" target=\"_blank\"><u>sarah.mccabe@sternir.com<\/u><\/a><\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1OTY1NyM1MTg4OTMyIzIxMjUwMzA=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/MTJmMGFjNDMtNTU3OC00NDAwLWI5YWUtYjU3ZmRjYzRkMWIxLTExMzY2MDE=\/tiny\/Cabaletta-Bio.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>PHILADELPHIA, Oct. 06, 2022 (GLOBE NEWSWIRE) &#8212; Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of targeted cell therapies for patients with autoimmune diseases, today announced that it will present clinical and translational data from the DesCAARTes\u2122 trial of DSG3-CAART in adults with mucosal-dominant pemphigus vulgaris (mPV) in a poster presentation at the upcoming 29th Annual Congress of the European Society of Gene &amp; Cell Therapy (ESGCT), which is being held at the Edinburgh International Conference Centre in Edinburgh, Scotland from October 11-14, 2022. Details of the poster presentation are as follows: Title: Characterization of DSG3-CAART cells prior to &amp; following adoptive transfer in mucosal Pemphigus VulgarisPoster ID Number: P370Session Title: Poster session &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cabaletta-bio-to-present-at-the-29th-annual-congress-of-the-european-society-of-gene-cell-therapy\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Cabaletta Bio to Present at the 29th Annual Congress of the European Society of Gene &amp; Cell Therapy&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-692871","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Cabaletta Bio to Present at the 29th Annual Congress of the European Society of Gene &amp; Cell Therapy - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cabaletta-bio-to-present-at-the-29th-annual-congress-of-the-european-society-of-gene-cell-therapy\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cabaletta Bio to Present at the 29th Annual Congress of the European Society of Gene &amp; Cell Therapy - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PHILADELPHIA, Oct. 06, 2022 (GLOBE NEWSWIRE) &#8212; Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of targeted cell therapies for patients with autoimmune diseases, today announced that it will present clinical and translational data from the DesCAARTes\u2122 trial of DSG3-CAART in adults with mucosal-dominant pemphigus vulgaris (mPV) in a poster presentation at the upcoming 29th Annual Congress of the European Society of Gene &amp; Cell Therapy (ESGCT), which is being held at the Edinburgh International Conference Centre in Edinburgh, Scotland from October 11-14, 2022. Details of the poster presentation are as follows: Title: Characterization of DSG3-CAART cells prior to &amp; following adoptive transfer in mucosal Pemphigus VulgarisPoster ID Number: P370Session Title: Poster session &hellip; Continue reading &quot;Cabaletta Bio to Present at the 29th Annual Congress of the European Society of Gene &amp; Cell Therapy&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/cabaletta-bio-to-present-at-the-29th-annual-congress-of-the-european-society-of-gene-cell-therapy\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2022-10-06T12:32:36+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1OTY1NyM1MTg4OTMyIzIxMjUwMzA=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cabaletta-bio-to-present-at-the-29th-annual-congress-of-the-european-society-of-gene-cell-therapy\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cabaletta-bio-to-present-at-the-29th-annual-congress-of-the-european-society-of-gene-cell-therapy\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Cabaletta Bio to Present at the 29th Annual Congress of the European Society of Gene &amp; Cell Therapy\",\"datePublished\":\"2022-10-06T12:32:36+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cabaletta-bio-to-present-at-the-29th-annual-congress-of-the-european-society-of-gene-cell-therapy\\\/\"},\"wordCount\":480,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cabaletta-bio-to-present-at-the-29th-annual-congress-of-the-european-society-of-gene-cell-therapy\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1OTY1NyM1MTg4OTMyIzIxMjUwMzA=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cabaletta-bio-to-present-at-the-29th-annual-congress-of-the-european-society-of-gene-cell-therapy\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cabaletta-bio-to-present-at-the-29th-annual-congress-of-the-european-society-of-gene-cell-therapy\\\/\",\"name\":\"Cabaletta Bio to Present at the 29th Annual Congress of the European Society of Gene &amp; Cell Therapy - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cabaletta-bio-to-present-at-the-29th-annual-congress-of-the-european-society-of-gene-cell-therapy\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cabaletta-bio-to-present-at-the-29th-annual-congress-of-the-european-society-of-gene-cell-therapy\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1OTY1NyM1MTg4OTMyIzIxMjUwMzA=\",\"datePublished\":\"2022-10-06T12:32:36+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cabaletta-bio-to-present-at-the-29th-annual-congress-of-the-european-society-of-gene-cell-therapy\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cabaletta-bio-to-present-at-the-29th-annual-congress-of-the-european-society-of-gene-cell-therapy\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cabaletta-bio-to-present-at-the-29th-annual-congress-of-the-european-society-of-gene-cell-therapy\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1OTY1NyM1MTg4OTMyIzIxMjUwMzA=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1OTY1NyM1MTg4OTMyIzIxMjUwMzA=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cabaletta-bio-to-present-at-the-29th-annual-congress-of-the-european-society-of-gene-cell-therapy\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Cabaletta Bio to Present at the 29th Annual Congress of the European Society of Gene &amp; Cell Therapy\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Cabaletta Bio to Present at the 29th Annual Congress of the European Society of Gene &amp; Cell Therapy - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/cabaletta-bio-to-present-at-the-29th-annual-congress-of-the-european-society-of-gene-cell-therapy\/","og_locale":"en_US","og_type":"article","og_title":"Cabaletta Bio to Present at the 29th Annual Congress of the European Society of Gene &amp; Cell Therapy - Market Newsdesk","og_description":"PHILADELPHIA, Oct. 06, 2022 (GLOBE NEWSWIRE) &#8212; Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of targeted cell therapies for patients with autoimmune diseases, today announced that it will present clinical and translational data from the DesCAARTes\u2122 trial of DSG3-CAART in adults with mucosal-dominant pemphigus vulgaris (mPV) in a poster presentation at the upcoming 29th Annual Congress of the European Society of Gene &amp; Cell Therapy (ESGCT), which is being held at the Edinburgh International Conference Centre in Edinburgh, Scotland from October 11-14, 2022. Details of the poster presentation are as follows: Title: Characterization of DSG3-CAART cells prior to &amp; following adoptive transfer in mucosal Pemphigus VulgarisPoster ID Number: P370Session Title: Poster session &hellip; Continue reading \"Cabaletta Bio to Present at the 29th Annual Congress of the European Society of Gene &amp; Cell Therapy\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/cabaletta-bio-to-present-at-the-29th-annual-congress-of-the-european-society-of-gene-cell-therapy\/","og_site_name":"Market Newsdesk","article_published_time":"2022-10-06T12:32:36+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1OTY1NyM1MTg4OTMyIzIxMjUwMzA=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cabaletta-bio-to-present-at-the-29th-annual-congress-of-the-european-society-of-gene-cell-therapy\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cabaletta-bio-to-present-at-the-29th-annual-congress-of-the-european-society-of-gene-cell-therapy\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Cabaletta Bio to Present at the 29th Annual Congress of the European Society of Gene &amp; Cell Therapy","datePublished":"2022-10-06T12:32:36+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cabaletta-bio-to-present-at-the-29th-annual-congress-of-the-european-society-of-gene-cell-therapy\/"},"wordCount":480,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cabaletta-bio-to-present-at-the-29th-annual-congress-of-the-european-society-of-gene-cell-therapy\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1OTY1NyM1MTg4OTMyIzIxMjUwMzA=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cabaletta-bio-to-present-at-the-29th-annual-congress-of-the-european-society-of-gene-cell-therapy\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/cabaletta-bio-to-present-at-the-29th-annual-congress-of-the-european-society-of-gene-cell-therapy\/","name":"Cabaletta Bio to Present at the 29th Annual Congress of the European Society of Gene &amp; Cell Therapy - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cabaletta-bio-to-present-at-the-29th-annual-congress-of-the-european-society-of-gene-cell-therapy\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cabaletta-bio-to-present-at-the-29th-annual-congress-of-the-european-society-of-gene-cell-therapy\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1OTY1NyM1MTg4OTMyIzIxMjUwMzA=","datePublished":"2022-10-06T12:32:36+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cabaletta-bio-to-present-at-the-29th-annual-congress-of-the-european-society-of-gene-cell-therapy\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/cabaletta-bio-to-present-at-the-29th-annual-congress-of-the-european-society-of-gene-cell-therapy\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cabaletta-bio-to-present-at-the-29th-annual-congress-of-the-european-society-of-gene-cell-therapy\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1OTY1NyM1MTg4OTMyIzIxMjUwMzA=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1OTY1NyM1MTg4OTMyIzIxMjUwMzA="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cabaletta-bio-to-present-at-the-29th-annual-congress-of-the-european-society-of-gene-cell-therapy\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Cabaletta Bio to Present at the 29th Annual Congress of the European Society of Gene &amp; Cell Therapy"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/692871","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=692871"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/692871\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=692871"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=692871"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=692871"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}